BTG (company)
BTG Limited is an international specialist healthcare company that is developing and commercialising products targeting critical care, cancer and other disorders. The current name was adopted when the British Technology Group changed its name on 27 May 1998. BTG was a constituent of the FTSE 250 Index until it was acquired by Boston Scientific in August 2019.
| Company type | Private limited company |
|---|---|
| Industry | Healthcare |
| Founded | 1991 as British Technology Group Ltd. |
| Headquarters | London, United Kingdom |
Key people | Garry Watts (Chairman of the board), Louise Makin (CEO), Duncan Kennedy (CFO) |
| Products | Development, manufacturing and commercialisation of specialty pharmaceuticals and interventional medicine in the areas of critical care, cancer and varicose veins. BTG also has a revenue stream from royalty payments on partnered products. |
| Revenue | £620.5 million (2018) |
| Parent | Boston Scientific |
| Website | www.btgplc.com |
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.